ArticleRedox biology2026
Endothelial MerTK impairment promotes cardiac dysfunction in the condition of high fat diet.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleCardiac fibrosis formation leads to cardiac dysfunction that is mainly caused by a high fat diet accompanied by an increased accumulation of apoptotic cells. MER proto-oncogene tyrosine kinase (MerTK) is a major receptor for efferocytosis, a process for the efficient clearance of apoptotic cells. This study was designed to investigate the novel role of endothelial MerTK in regulating cardiac dysfunction in the condition of high fat diet.
methodsMerTK deficiency in endothelial cells (MerTK
resultsThe proteomics data showed that mitochondrial dysfunction, increased apoptosis and necrosis, defective phagosome formation, and impaired engulfment of cells represent the main signaling pathways involved in endothelial MerTK-mediated cardiac dysfunction. The immunostaining data indicates that endothelial MerTK deficiency promotes NADPH oxidases activation, cardiac fibrosis formation, phenotypic switching in smooth muscle cells (SMCs) and pro-inflammation response, while inhibiting expression of Apolipoprotein E (ApoE), all are key drivers to accelerate cardiac dysfunction. The scRNA-seq analysis in mouse hearts highlights the importance of endothelial functions in cardiac hypertrophy. The snRNA-seq analysis reveals endothelial MerTK dynamics in cardiac dysfunction based on specimens from human patients with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM).
conclusionsThese findings provide compelling evidence that endothelial MerTK impairment is a novel mechanism in promoting cardiac dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.